828 Shares in Regeneron Pharmaceuticals, Inc. $REGN Bought by Integrated Advisors Network LLC

Integrated Advisors Network LLC bought a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the 1st quarter, HoldingsChannel reports. The institutional investor bought 828 shares of the biopharmaceutical company’s stock, valued at approximately $639,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in REGN. Norges Bank acquired a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth about $1,012,296,000. Price T Rowe Associates Inc. MD lifted its holdings in shares of Regeneron Pharmaceuticals by 142.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,949,797 shares of the biopharmaceutical company’s stock valued at $1,504,991,000 after purchasing an additional 1,144,887 shares in the last quarter. Nuveen LLC grew its position in shares of Regeneron Pharmaceuticals by 71.1% in the 4th quarter. Nuveen LLC now owns 2,010,517 shares of the biopharmaceutical company’s stock valued at $1,551,858,000 after purchasing an additional 835,240 shares during the period. Dodge & Cox grew its position in shares of Regeneron Pharmaceuticals by 18.9% in the 3rd quarter. Dodge & Cox now owns 4,550,845 shares of the biopharmaceutical company’s stock valued at $2,558,804,000 after purchasing an additional 724,562 shares during the period. Finally, Wellington Management Group LLP increased its stake in Regeneron Pharmaceuticals by 8,620.0% during the 4th quarter. Wellington Management Group LLP now owns 664,465 shares of the biopharmaceutical company’s stock worth $512,881,000 after purchasing an additional 656,845 shares in the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Regeneron Pharmaceuticals

In related news, Director Arthur F. Ryan sold 200 shares of the business’s stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total transaction of $130,030.00. Following the transaction, the director directly owned 17,303 shares in the company, valued at approximately $11,249,545.45. The trade was a 1.14% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 6.97% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have commented on REGN. BMO Capital Markets dropped their target price on shares of Regeneron Pharmaceuticals from $900.00 to $730.00 and set an “outperform” rating on the stock in a report on Monday, May 18th. TD Cowen upped their price target on shares of Regeneron Pharmaceuticals from $880.00 to $960.00 and gave the company a “buy” rating in a report on Thursday, April 23rd. Guggenheim increased their price objective on shares of Regeneron Pharmaceuticals from $975.00 to $995.00 and gave the stock a “buy” rating in a research report on Friday, May 1st. Weiss Ratings restated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a report on Wednesday, June 24th. Finally, Royal Bank Of Canada cut their price objective on shares of Regeneron Pharmaceuticals from $707.00 to $696.00 and set a “sector perform” rating on the stock in a research report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $787.67.

Regeneron Pharmaceuticals Stock Performance

REGN opened at $667.95 on Friday. The business’s 50-day simple moving average is $645.74 and its 200 day simple moving average is $722.80. Regeneron Pharmaceuticals, Inc. has a 52-week low of $541.00 and a 52-week high of $821.11. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.96 and a current ratio of 3.57. The firm has a market capitalization of $70.62 billion, a PE ratio of 16.28, a PEG ratio of 1.46 and a beta of 0.24.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share for the quarter, topping the consensus estimate of $8.91 by $0.56. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The firm had revenue of $3.61 billion for the quarter, compared to analyst estimates of $3.48 billion. During the same quarter in the previous year, the firm earned $8.22 EPS. The business’s quarterly revenue was up 19.0% on a year-over-year basis. As a group, sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.4 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, June 4th. Investors of record on Wednesday, May 20th were paid a $0.94 dividend. The ex-dividend date of this dividend was Wednesday, May 20th. This represents a $3.76 annualized dividend and a dividend yield of 0.6%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 9.16%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.